has begun substantial efforts to add to its success by expanding into the biotechnology arena. As a result, a new acquisition of a pancreatic cancer treatment technology will initiate our growth and expansion into this area. The present status of this includes completed initial clinical trials in Europe with multiple directions for forward movement which are presently in the planning and initiation stages.